GeneReach Biotechnology (4171) — Financial Flexibility Index
GeneReach Biotechnology (4171) has a Financial Flexibility Index of 0.06x as of December 2025. Free cash flow of NT$16.62 Million (operating CF NT$12.05 Million minus capex NT$4.58 Million) represents 0% of total liabilities (NT$284.34 Million). Check 4171 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
GeneReach Biotechnology Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for GeneReach Biotechnology across 9 annual periods. See working capital position of GeneReach Biotechnology to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for GeneReach Biotechnology (2017–2025)
Year-by-year free cash flow to debt coverage for GeneReach Biotechnology. For the full company profile including market capitalisation, see GeneReach Biotechnology market capitalisation.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.01x | NT$-1.88 Million | NT$-13.52 Million | NT$284.34 Million | ▲ +84.7% |
| 2024 | -0.04x | NT$-14.76 Million | NT$-23.22 Million | NT$341.00 Million | ▼ -20.0% |
| 2023 | -0.04x | NT$-11.32 Million | NT$-38.67 Million | NT$313.71 Million | ▼ -104.7% |
| 2022 | 0.78x | NT$402.54 Million | NT$357.63 Million | NT$519.23 Million | ▲ +26.7% |
| 2021 | 0.61x | NT$364.78 Million | NT$348.99 Million | NT$596.35 Million | ▼ -0.2% |
| 2020 | 0.61x | NT$234.69 Million | NT$169.82 Million | NT$382.75 Million | ▲ +4297.5% |
| 2019 | 0.01x | NT$2.34 Million | NT$-11.19 Million | NT$167.82 Million | ▼ -33.7% |
| 2018 | 0.02x | NT$8.05 Million | NT$5.74 Million | NT$382.68 Million | ▲ +225.0% |
| 2017 | -0.02x | NT$-5.93 Million | NT$-6.83 Million | NT$352.21 Million | — |